Biomarker-based subtyping of depression and anxiety disorders using Latent Class Analysis. A NESDA study

Lian Beijers1, Klaas J. Wardenaar1, Fokko J. Bosker2, Femke Lamers3, Gerard van Grootheest3, Marrit K. de Boer2, Brenda W.J.H. Penninx1 and Robert A. Schoevers2

1Department of Psychiatry, University of Groningen, University Medical Center Groningen, Interdisciplinary Center Psychopathology and Emotion regulation (ICPE), Groningen, The Netherlands; 2Department of Psychiatry, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands and 3GGZ inGeest and Department of Psychiatry, Amsterdam Public Health Research Institute, VU University Medical Center, Amsterdam, The Netherlands

Abstract

Background. Etiological research of depression and anxiety disorders has been hampered by diagnostic heterogeneity. In order to address this, researchers have tried to identify more homogeneous patient subgroups. This work has predominantly focused on explaining interpersonal heterogeneity based on clinical features (i.e. symptom profiles). However, to explain interpersonal variations in underlying pathophysiological mechanisms, it might be more effective to take biological heterogeneity as the point of departure when trying to identify subgroups. Therefore, this study aimed to identify data-driven subgroups of patients based on biomarker profiles.

Methods. Data of patients with a current depressive and/or anxiety disorder came from the Netherlands Study of Depression and Anxiety, a large, multi-site naturalistic cohort study (n = 1460). Thirty-six biomarkers (e.g. leptin, brain-derived neurotrophic factor, tryptophan) were measured, as well as sociodemographic and clinical characteristics. Latent class analysis was used to identify different patient clusters.

Results. The analyses resulted in three classes, which were primarily characterized by different levels of metabolic health: ‘lean’ (21.6%), ‘average’ (62.2%) and ‘overweight’ (16.2%). Inspection of the classes’ clinical features showed the highest levels of psychopathology, severity and medication use in the overweight class.

Conclusions. The identified classes were strongly tied to general (metabolic) health, and did not reflect any natural cutoffs along the lines of the traditional diagnostic classifications. Our analyses suggested that especially poor metabolic health could be seen as a distal marker for depression and anxiety, suggesting a relationship between the ‘overweight’ subtype and internalexalizing psychopathology.

Introduction

Depression and anxiety are highly prevalent and associated with a substantial burden on both patients, their caregivers and society as a whole (Kessler, 2012; Whiteford et al., 2016; World Health Organization (WHO), 2016). The overlap between depressive and anxiety symptoms and disorders is the rule rather than the exception, and much of the same treatments are currently used for patients in both diagnostic categories (Nutt et al., 2002; Hettema, 2008; Goldberg, 2011). Despite the many research efforts that have been made over the past decades, the etiological mechanisms underlying depressive and anxiety disorders are still poorly understood, which is partially due to the heterogeneous nature of the patient population (Kendler, 2014; Monroe and Anderson, 2015), resulting in small to moderate observed treatments effects (Turner and Rosenthal, 2008; Cuijpers et al., 2010; Cooney, 2013; Roest et al., 2015). Scientific progress is more likely if the problem of diagnostic heterogeneity is effectively addressed. Unfortunately, more homogeneous clinical subtypes have been shown to be weakly associated with etiology, the course of illness, and treatment response (Baumeister and Parker, 2012). Alternative data-driven subtype classifications based on cluster analyses (Labke and Muthén, 2005; Hastie et al., 2011; Van Loo et al., 2012), have also been shown to have limited associations with specific etiological mechanisms (Van Loo et al., 2012; Marquand et al., 2016). This limited association with etiology might be explained by the fact that these subtypes are primarily optimized to differentiate between symptom patterns and not between biological...
mechanisms (Hasler et al., 2004). Subtypes might be more suitable to investigate etiological heterogeneity when biological profiles are used as the point of departure.

It has been acknowledged that theories assuming that there is a single biological disturbance underlying depression in all patients (e.g. monoamine deficiency) have limited validity (Kendell and Jablensky, 2003; Hasler, 2010; Kapur et al., 2012). Rather, the specific disturbances are likely to differ between patients, even with similar symptomatology and/or diagnoses (Insel et al., 2010). If we consider this, the low observed effect sizes in treatment trials could be explained by the fact that only in part of the patients treated with a certain compound (e.g. selective serotonin reuptake inhibitors), the treatment actually affects their individual biological disturbances (Tang et al., 2010). Identification of more homogeneous biomarker-based subtypes in the patient population could help to gain more insight into patient-specific etiological mechanisms and to better target treatments to those that are likely to benefit (Meyer and Ginsburg, 2002; Bartova et al., 2010; Leuchter et al., 2010; Simon and Perlis, 2010; Simon, 2011; e Silva, 2013; Miller and O’Callaghan, 2013; Ozomaro et al., 2013; Cuijpers et al., 2016; Korte et al., 2015).

To our knowledge, the existence of depression/anxiety subtypes with different biological disturbance profiles and their manifest clinical characteristics have not been extensively studied before. Therefore, this study aimed to identify biomarker-based subtypes using latent class analysis (LCA) a large and well-phenotyped sample of depressive and/or anxiety patients (n = 1460). In this sample, 36 biomarkers were measured, representing different underlying mechanisms that have previously been found to be relevant to depression and anxiety disorders (e.g. hypothalamus-pituitary-adrenal axis function, inflammation). Next, in order to investigate the clinical relevance and utility of the identified biomarker-based subtypes, clinical characteristics and symptomatology were compared across the identified classes.

Methods and materials
Participants and procedures
The Netherlands Study of Depression and Anxiety (NESDA) is a multisite naturalistic cohort study that aims to examine the long-term course of depressive and anxiety disorders. A detailed description of the NESDA study design and sampling procedures can be found elsewhere (Penninx et al., 2008). In brief, the NESDA cohort consists of 2981 subjects, aged 18–65 years, with (a history of) anxiety and/or depressive disorder and healthy controls. The research protocol was approved by the Medical Ethical Committees of participating institutes, and after complete description of the study, all respondents provided written informed consent. For the present study, all 1460 subjects with a current (last month) diagnosis of a depressive or anxiety disorder according to the Composite International Diagnostic Interview (CIDI; WHO version 2.1) were selected. For additional analyses (see below), 634 healthy control subjects were added to the dataset.

Measurements
During a 4-hour baseline assessment including interviews, a medical examination, a cognitive computer task and collection of blood samples, extensive information was gathered about key (mental) health outcomes and demographic, psychosocial, clinical and biological determinants. Additional measures (written questionnaires and saliva samples) were carried out at home by the participants. Diagnostic and statistical manual of mental disorders-fourth edition (DSM-IV) diagnoses of depressive [minor depression, dysthymia and major depressive disorder (MDD)] and anxiety disorders (generalized anxiety disorder, social phobia, agoraphobia and panic disorder) were established using the Composite International Diagnostic Interview (CIDI) 2.1. Depression symptom severity was measured with the 30-item Inventory of Depressive Symptomatology Self Report (IDS-SR) (Rush et al., 1996). Anxiety symptom severity was measured with the Beck Anxiety Inventory (BAI) (Beck et al., 1988). Sociodemographic information included age, sex, number of chronic diseases, drinking and smoking behavior. The biological data consisted of waist circumference, body mass index (BMI), blood pressure (systolic/diastolic and the ankle-brachial index), heart rate variability and markers from blood and saliva samples. A summary of the biological methods is provided below. For more details, see online Supplementary Table S1.

Blood markers
Venous blood was drawn prior to the interview session (between 8:00 and 9:00 am) after an overnight fast. Venous blood samples were transferred to a local lab for routine assessments; serum and plasma were spun down within an hour and stored at −80 °C for later analyses. The routine assays included hematological variables (hemoglobin, hematocrit, and erythrocyte count), liver function (γ-glutamyltransferase, aspartate aminotransferase, alanine aminotransferase) and kidney function (creatinine), as well as markers related to the metabolic syndrome (MetS) and obesity (glucose, cholesterol, triglycerides, HDL- and LDL-cholesterol, thyroid-stimulating hormone, free thyroxine). Additional biomarkers are described below. Most of these markers’ associations with mental-health outcomes have previously been established (Chaves et al., 2004; Vancampfort et al., 2014; Hiles et al., 2016).

Inflammation. C-reactive protein (hsCRP) was measured in duplicate by an in-house enzyme-linked immunosorbent assay (ELISA), based on purified protein and polyclonal anti-hsCRP antibodies (Dako, Glostrup, Denmark). Plasma IL-6 levels were measured in duplicate by a high sensitivity ELISA (PeliKine Compact TM ELISA, Sanquin, Amsterdam, The Netherlands). Plasma tumor necrosis factor alpha (TNF-α) levels were assayed in duplicate using a high-sensitivity solid phase ELISA (Quantikine™ HS Human TNF- α Immunoassay, R&D systems Inc, Minneapolis, MN, USA). Tryptophan and (OH-)kynurenine concentrations were assayed by an automated online solid-phase extraction-liquid chromatographic-tandem mass spectrometric (XLC-MS/MS) method. Both inflammation and degradation of tryptophan along the kynurenine pathway have been found to be associated with depression in this sample (Lamers et al., 2013; Quak et al., 2014).

Neuroplasticity. Brain-derived neurotrophic factor (BDNF) protein levels were measured in serum samples using the Emax Immuno Assay system from Promega (Madison, WI, USA). IGF-I (nmol/l) was assayed centrally by chemiluminescence immunoassay of EDTA plasma on the Liaison autoanalyzer (DiaSorin, S.p.A., Italy). Both measures have previously been found to be associated with depression with melancholic features in this sample (Patas et al., 2014).
Measurements were taken at awakening [T1], 30 [T2], 45 [T3] minutes later, and in the evening (22:00 [T4] and 23:00 [T5]). Additionally, the dexamethasone suppression test (DST) was carried out by oral administration of a 0.5 mg dexamethasone pill directly after T6 and a final cortisol measurement the next morning at awakening (T7).

Steroid hormones. Dehydroepiandrosterone and its sulfate conjugate (DHEA-/S) were determined using a delayed one-step immunoassay with a chemiflex assay protocol. Sex Hormone Binding Globulin (SHBG) was determined using a two-step immunoassay with a chemiflex assay protocol. Total estradiol (E2) was determined using a delayed one-step immunoassay with a chemiflex assay protocol. Previously, steroid hormones were found to be associated with anxiety and depression in this sample (Milaneschi et al., 2014).

Leptin. Plasma leptin concentrations were measured in EDTA plasma using an ELISA kit (Human Leptin ELISA Kit; Linco Research, Inc, St. Charles, Missouri). Leptin has previously been investigated by using two-tailed χ² statistics for categorical variables and one-way analysis of variance statistics for continuous variables, or by using the Kruskall–Wallis test if the outcomes were not normally distributed. The False Discovery Rate controlling procedure was used to counteract the problem of multiple comparisons (Benjamini and Hochberg, 1995). All comparisons were conducted using SPSS for Windows, version 23 (IBM Inc., USA). To evaluate if the identified class structure was specifically informative about the biological heterogeneity in depressed/anxious patients or was more broadly reflective of normal biological variations in the population as a whole, all analyses were rerun in a dataset including both patients and healthy controls (n = 2094).

Data preprocessing
Clinically determined cut-off values to categorize the biomarker variables were available for some but not all biomarkers. Therefore, an alternative approach was taken, categorizing every variable based on percentiles, with the lowest and highest scoring 10th percentile of all subjects being coded as −1 and 1, respectively, and the middle 80% being coded 0. The 10th percentile cut-off was chosen to make sure that especially the more extreme, potentially clinically relevant variations in biomarker levels would be represented in the eventual LCA model. Setting the cut-offs at higher percentile values would lead to biomarker variables with more subjects in both the lower and upper category, but with a more within-category variation of biomarker levels. This makes the categorization potentially less useful for differentiation between subjects with distinct biomarker patterns as relevant interpersonal differences are eliminated by pooling patients with different biomarker levels in the same category. Indeed, exploratory analyses using 25th and 50th percentiles as cutoffs led models with many classes (i.e. the AIC and BIC kept decreasing with each class addition) that could not be easily distinguished from each other in terms of their specific biomarker patterns. In the final coding scheme, the number of subjects per decile varied between
8% and 12%, because in some cases a large number of subjects had the same score, and we chose to use the percentile closest to 10. The above-described coding was done separately for different sex/age (<30, 30–50, >50) strata, because the distributions of some biological variables are known to differ across sex and age (e.g. testosterone). Differences between classes on other potentially relevant covariates were investigated after identification of the optimal latent class model.

To ensure that the model solution would not be driven by the fact that some variables were essentially measuring the same thing, all variables with a correlation above 0.75 before recoding were summed after categorization (i.e. the hematological markers, the heart rate variability reactivity in both test conditions, systolic and diastolic blood pressure, aspartate and alanine aminotransferase). Subjects with a score of $\leq -1$ got a value of $-1$, those with a score of 0 got a value of 0 and subjects with a score of $\geq 1$ got a value of 1 on a newly constructed compound variable. Recoding was done using SPSS for Windows, version 23 (IBM Inc., USA).

The final dataset included 36 biological variables.

### Results

The LCA results are shown in Table 1. The lowest BIC combined with adequate entropy indicated that the 3-class model best described the data. Although the AIC decreased for the more complex models up to six classes, these models were less optimal in terms of parsimony and showed only marginally higher

| Classes | DF   | AIC   | BIC   | H    |
|---------|------|-------|-------|------|
| 2       | 149  | 61,930.889 | 62,718.531 | 0.725 |
| 3       | 224  | 61,360.457 | 62,544.564* | 0.765 |
| 4       | 299  | 61,079.887 | 62,660.458 | 0.756 |
| 5       | 374  | 60,934.908 | 62,911.944 | 0.765 |
| 6       | 449  | 60,807.111* | 63,180.612 | 0.797* |

*Most favorable score.

DF, Degrees of Freedom; AIC, Akaike Information Criterion; BIC, Bayesian Information Criterion; H, Entropy.

![Fig. 1](https://www.cambridge.org/core/core/10107)
| Hypothesis                | Variable (Abbreviation, unit) | Lean \((N = 311)\) | Average \((N = 910)\) | Overweight \((N = 239)\) | \(p^*\) |
|--------------------------|-------------------------------|---------------------|------------------------|---------------------------|---------|
| **Neuroplasticity**      | Brain-derived neurotrophic factor (BDNF, ng/ml) | 8.66 (3.13) | 9.28 (3.66) | 9.19 (3.67) | 0.033 |
|                          | Insulin-like Growth Factor 1 ([IGF-1, nmol/l]) | 25.1 (8.7) | 26.88 (8.42) | 23.15 (7.87) | 0.000^{a,b} |
| **Mineral balance**      | Vitamin D (nmol/l)            | 62.84 (33.92) | 63.14 (27.52) | 47.02 (23.25) | 0.000^{a,c} |
|                          | Parathyroid hormone (PTH, pmol/l) | 5.25 (2.22) | 5.60 (2.24) | 7.16 (3.18) | 0.000^{a,b,c} |
| **Inflammation**         | C-reactive protein (hsCRP, mg/l) | 1.58 (2.82) | 2.68 (4.9) | 6.65 (7.82) | 0.000^{b,c} |
|                          | Interleukin 6 (IL-6, pg/ml)   | 1.05 (1.18) | 2.00 (23.44) | 1.81 (3.67) | 0.000^{b,c} |
|                          | Tumor necrosis factor alpha (TNF-\(\alpha\), pg/ml) | 0.87 (0.94) | 1.13 (1.54) | 1.25 (1.32) | 0.000^{b,c} |
|                          | Tryptophan (\(\mu\)mol/l)    | 58.75 (11.54) | 65.57 (13.17) | 65.58 (15.51) | 0.000^{a,b,c} |
|                          | Kynurenine (\(\mu\)mol/l)    | 1.84 (0.53) | 2.32 (0.59) | 2.48 (0.84) | 0.000^{b,c} |
|                          | 3-hydroxykynurenine (nmol/l) | 24.18 (11.42) | 32.06 (13.08) | 37.81 (19.79) | 0.000^{a,b,c} |
| **Stress response**      | Area under the curve with respect to the ground \(\text{AUCg,} \ \mu\text{g/dl/h}\) | 19.98 (7.18) | 19.34 (7.35) | 17.48 (6.41) | 0.012^{a,c} |
|                          | Area under the curve with respect to the increase \(\text{AUCi,} \ \mu\text{g/dl/h}\) | 3.30 (5.92) | 2.43 (6.68) | 1.61 (5.38) | 0.047 |
|                          | Evening cortisol (nmol/l)     | 5.92 (3.76) | 5.29 (3.23) | 5.36 (2.63) | 0.017^{a} |
|                          | Dexamethasone (DST) cortisol-suppression | 0.38 (0.17) | 0.39 (0.24) | 0.31 (0.25) | 0.001^{a,c} |
| **Heart rate variability** | Mean root mean square of successive differences \(\text{RMSSD}\) | 47.53 (39.11) | 41.60 (31.63) | 31.91 (28.69) | 0.000^{a,b,c} |
|                          | Difference from baseline to computer task | 8.93 (18.94) | 4.80 (23.4) | 0.65 (22.5) | 0.000^{b,c} |
|                          | Difference from resting baseline to interview | 6.65 (14.13) | 3.59 (17.5) | 0.40 (16.7) | 0.000^{b,c} |
| **Hematology**           | Hemoglobin (Hb, nmol/l)       | 8.50 (0.80) | 8.72 (0.78) | 8.76 (0.89) | 0.000^{c} |
|                          | Hematocrit (HT, L/L)          | 0.40 (0.04) | 0.41 (0.03) | 0.42 (0.04) | 0.000^{c} |
|                          | Erythrocytes \((\times10^{12}/l)\) | 4.48 (0.42) | 4.65 (0.4) | 4.75 (0.43) | 0.000^{b,c} |
| **Steroid hormones**     | Dehydroepiandrosterone (DHEA, nmol/ml) | 25.50 (16.21) | 22.49 (16.15) | 19.08 (16.04) | 0.000^{a,b,c} |
|                          | Dehydroepiandrosterone sulphate (DHEA-S, \(\mu\)mol/l) | 6.55 (3.61) | 6.25 (3.65) | 5.39 (3.66) | 0.000^{b,c} |
|                          | Sex hormone-binding globulin (SHBG, nmol/l) | 85.38 (66.9) | 60.69 (51.65) | 45.29 (39.04) | 0.000^{b,c} |
|                          | Estradiol (E2, nmol/l)        | 0.49 (5.37) | 0.26 (2.69) | 0.17 (0.18) | 0.088 |
|                          | Testosterone (nmol/l)         | 10.52 (11.3) | 8.54 (8.62) | 7.24 (7.54) | 0.001^{a,b} |
| **Kidney function**      | Creatinine (mg/dl)           | 0.73 (0.14) | 0.76 (0.15) | 0.76 (0.26) | 0.007^{c} |
| **Liver function**       | Gamma-glutamyltransferase (gamma-GT, U/L) | 22.19 (27.56) | 22.66 (17.67) | 43.67 (39.75) | 0.000^{a,b} |
|                          | Alanine aminotransaminase (ALAT, U/L) | 19.29 (11.74) | 22.91 (16.43) | 34.95 (28.54) | 0.000^{b,c} |
|                          | Aspartate aminotransferase (ASAT, U/L) | 23.83 (9.86) | 25.45 (10.61) | 29.69 (13.73) | 0.000^{a,b,c} |
| **Metabolic markers**    | Waist circumference (cm)      | 77.85 (9.30) | 88.88 (10.65) | 108.43 (14.06) | 0.000^{b,c} |
|                          | Body Mass Index               | 21.45 (2.77) | 25.33 (3.55) | 33.13 (5.81) | 0.000^{b,c} |
|                          | Glucose (mmol/l)              | 5.01 (1.15) | 5.16 (0.77) | 5.74 (1.58) | 0.000^{b,c} |
|                          | Low-density lipoproteins (LDL, mmol/l) | 2.73 (0.91) | 3.22 (0.98) | 3.40 (0.99) | 0.000^{b,c} |
|                          | High-density lipoproteins (HDL, mmol/l) | 1.85 (0.50) | 1.59 (0.39) | 1.38 (0.40) | 0.000^{b,c} |
|                          | Triglycerides (mmol/l)        | 0.97 (0.51) | 1.29 (0.81) | 1.96 (1.12) | 0.000^{a,b,c} |
|                          | Blood pressure, systolic (Bp, mm Hg) | 130.41 (17.5) | 136.37 (20.01) | 144.04 (17.58) | 0.000^{a,b,c} |
|                          | Blood pressure, diastolic (Bp, mm Hg) | 78.45 (9.74) | 82.11 (11.29) | 88.48 (10.62) | 0.000^{b,c} |
|                          | Ankle brachial pressure index (ABPI) | 1.14 (0.15) | 1.14 (0.16) | 1.15 (0.16) | 0.345 |
|                          | Leptin (\(\mu\)g/l)          | 7.26 (6.60) | 14.94 (10.49) | 31.06 (18.28) | 0.000^{b,c} |
|                          | Thyroid-stimulating hormone (TSH, mU/l) | 2.59 (3.57) | 2.49 (1.51) | 2.80 (3.23) | 0.245 |

(Continued)
entropy. For each class, Fig. 1 shows the probabilities of biomarker scores in the top or bottom 10\textsuperscript{th} percentile. Table 2 shows the distribution of biomarkers across the three latent classes. Most biomarkers differed among classes, with the notable exception of the cortisol-related biomarkers. Waist circumference, BMI and leptin had the largest effect (Cramer’s \( V > 0.5 \)) on the model solution and were used to inform class labeling. Other variables (e.g. measures on inflammation and steroid hormones) showed smaller, but still meaningful, variation between classes (Cramer’s \( V = 0.335–0.209 \), see Table 3).

The first class was labeled ‘lean’ (\( n = 311 \)) because it was associated with a healthy BMI and a comparatively high probability of being in the bottom 10\textsuperscript{th} percentile for the obesity/MetS markers. The second class was labeled ‘average’ (\( n = 910 \)) because it showed a low probability for extreme scores on any of the biomarkers. The third class was labeled ‘overweight’ (\( n = 239 \)) and was characterized by a pattern of probabilities almost perpendicular to the lean class, with comparatively high probabilities to be in the upper 10\textsuperscript{th} on obesity and MetS-related markers.

Table 4 shows the distribution of clinical characteristics across the three identified latent classes. As expected because of the pre-stratified processing of the data, the classes did not differ with respect to gender or age. The lean and average classes were similar in terms of diagnoses, whereas subjects in the overweight class were more likely to suffer from MDD. Persons in the overweight class were also more likely to endorse the atypical depressive subtype and to use psychotropic medication, specifically tricyclic antidepressants. Overweight subjects also had higher scores on both the IDS and the BAI. The lean class had a lower age of onset compared to the other classes (i.e. 18.1 v. 21.6 v. 22.6). There were no differences in course or diagnoses at 2 and 6 years follow-up (see online Supplementary Table S2). Individual symptoms of depression and anxiety did not differ between classes (data not shown).

LCA in the combined sample of patients and healthy controls (see online Supplementary Table S3) again showed a 3-class model to be optimal. The classes were very similar to the original model with regard to their respective biomarker profiles (see online Supplementary Fig. S1). When compared across the classes, the percentage of subjects with current psychopathology was higher in the overweight class, whereas the percentages of patients and controls in the lean class were equal (see online Supplementary Table S4).

### Discussion

This study aimed to use LCA in to identify subgroups with different biomarker profiles in a large sample of patients with depressive and anxiety disorders. A lean (21.6\%), an average (62.2\%) and an overweight (16.2\%) class were identified. Overall, the model seemed to reflect somatic health status, which was confirmed by the observation of similar classes when healthy controls were included in the sample. Still, the fact that the subjects with psychopathology were relatively likely to be in the ‘overweight’ class compared with healthy controls, indicates a possible connection between these disorders and the overweight biomarker profile. Furthermore, we found that the lean group had a significantly lower age of onset compared to the other two groups (see Table 4). Although the mean ages of onset are all in early adulthood and relatively close to each other, it cannot be excluded that there may be subtle differences in etiological mechanisms.

These bottom-up findings align with findings from research that used a more top-down approach and showed an association between depression and anxiety and obesity/MetS in this sample (van Reedt Dortland et al., 2009; Van Reedt Dortland et al., 2010), and with results from large-scale meta-analyses (Blaine, 2008; Luppino et al., 2010; Sardinha and Nardi, 2014; Vancampfort et al., 2014; Ghanai Gheslagh et al., 2015; Mannan et al., 2016). The exact mechanisms behind these associations are unclear, partially because the (bi)directional nature of the association is still a point of discussion (Blaine, 2008; Ghanai Gheslagh et al., 2015; Hiles et al., 2016; Mannan et al., 2016). Obesity might cause depression and anxiety through social or biological mechanisms, but it might also be that the excessive weight gain is caused by the unhealthy lifestyle habits of patients. Medication use is another risk factor, as it is becoming apparent that many commonly used psychotropic medications such as antidepressants are associated with cardiometabolic risk factors such as insulin resistance, obesity, and dyslipidemia (Abosi et al. 2018). Evidence from the current sample supports this hypothesis. We found that psychotropic medication use is higher in the overweight subtype, and previous research in this sample showed a directional relationship between medication use and waist circumference and MetS (Hiles et al., 2016). Another interesting hypothesis is that depression and the MetS share a common cause, for instance, genetic risk factors (Bornstein et al., 2006). Indeed, some evidence indicates that MetS and depression are caused by similar alterations of the stress system, including the hypothalamic-pituitary-adenal axis, the autonomic nervous system, the immune system, and platelet and endothelial function (Van Reedt Dortland et al., 2010; Luppino et al., 2014; Marazziti et al., 2014; Vancampfort et al., 2014; Vogelzangs et al., 2014).

However, we found no association between the overweight subtype and course or diagnoses at 2- and 6-year follow-up. It is possible that no such association exists, but there are alternative explanations. It is possible that other causal factors (not shared between depression and the MetS) obfuscated the results. Furthermore, in this sample, it has been shown that especially MDD subjects (with and without comorbid anxiety) are more
likely to change weight compared to controls (de Wit et al., 2015; Gibson-Smith et al., 2016). If subsequent biomarker changes also occurred, these subjects might have switched subtypes, and it might be that this change in subtype would have been more informative with respect to course than baseline subtype membership. Unfortunately, the current data did not allow for investigation of subtype changes because biomarker data needed to do so was not available at follow-up.

In accordance with previous symptom-based subtyping research (Van Loo et al., 2012; Rhebergen et al., 2013; de Vos et al., 2015; Wardenaar et al., 2017) this study does not provide a bottom-up validation for the DSM-diagnosis categories of depression and anxiety disorders as patients with different diagnoses did not cluster into distinct biological classes. Also, in contrast to previous research (Cizza et al., 2012; Lamers et al., 2013; Lojko et al., 2015; Milaneschi et al., 2017), we did not find an association between the latent classes and atypical v. melancholic features of depression. When comparing melancholic and atypical symptomatology on the IDS-SR (Rush et al., 1996) between classes, the only significant difference was that the overweight class showed a higher percentage of atypical specifiers compared to the lean class. However, in absolute terms, both atypical and melancholic IDS-SR counts were highest for the overweight class (although differences on the melancholic subscale were no longer significant after correction for multiple comparisons).

Overall, the results indicate that biomarker heterogeneity among depressive and/or anxiety patients mostly reflects variations in somatic health that extend into the part of the population without mental health problems. However, this does not mean that part of these biological variations is not also related to psychological health. As stated above, variations in somatic health are known to be strongly related to variations in psychopathology. Additionally, there may be smaller but still relevant associations between specific sets of biomarkers and depression/ anxiety that were not detected in the current analyses but could be of strong interest for the development of more personalized etiological models. A future methodological challenge lies in better investigating if generic somatic-health-related biological effects can be separated from more specific psychopathology-related biological effects. Possibilities for this may lie in the use of more flexible clustering algorithms, but also in the combination of biomarker and clinical data in the identification of subtypes. With regard to the biomarkers that could be investigated deeper, the current results suggested that there were several biomarkers that had smaller effects in the LCA results than the MetS biomarkers, but could still be potentially interesting as targets for further research, such as inflammation-related markers (e.g. Kynurenine, hsCRP) or sex-related markers (e.g. SHGB, testosterone).

### Strengths and limitations

Strengths of the current study included the large sample size, the broad range of available biomarkers, and the presence of thorough clinical assessments. However, the results should also be interpreted in the context of several limitations. First, the results apply to a group of outpatients and results cannot be directly translated to other groups (e.g. inpatients). Second, LCA makes very strong assumptions (e.g. local independence) that enable LCA to estimate interpretable but strongly simplified models. However, we believe that (the violation of) the assumption of local independence is not a driving force in our model, because we made sure not to include strongly correlated pairs of biomarkers and found classes that were not defined by specific clusters of correlated biomarkers but rather by a collection of biomarkers from different domains (see Table 2). Third, the possible negative

---

### Table 3. Cramer’s V values for each biological variable in the 3-class model based on the sample of subjects with current psychopathology

| Variable                                      | Cramer’s V |
|-----------------------------------------------|------------|
| Waist circumference                           | 0.606      |
| Body mass index                               | 0.585      |
| Leptin                                        | 0.518      |
| Kynurenine                                    | 0.335      |
| C-reactive protein                            | 0.282      |
| Sex hormone binding globulin                  | 0.275      |
| Gamma-glutamyltransferase                     | 0.270      |
| Triglycerides                                 | 0.264      |
| Ankle-brachial index                          | 0.260      |
| Oh-kynurenine                                 | 0.258      |
| Glucose                                       | 0.233      |
| Testosterone                                  | 0.214      |
| HDL-cholesterol                               | 0.209      |
| Parathyroid hormone                           | 0.173      |
| Liver values (combined asat/alat)             | 0.168      |
| Blood pressure (combined systolic/diastolic)  | 0.164      |
| Tryptophan                                    | 0.156      |
| Heart rate reactivity (combined from both tests)| 0.154    |
| Blood values (combined hb, ht, ethrocytes)    | 0.151      |
| Ldl-cholesterol                               | 0.148      |
| Insulin-like growth factor 1                  | 0.142      |
| Interleukin 6                                 | 0.139      |
| Dehydroepiandrosterone                        | 0.134      |
| Dehydroepiandrosterone-sulphate              | 0.128      |
| 25-hydroxyvitamin d                           | 0.118      |
| Dexamethasone suppression test                | 0.107      |
| Aucl                                           | 0.091      |
| Free thyroxine                                | 0.091      |
| Tumor necrosis factor alpha                   | 0.089      |
| Estradiol                                     | 0.082      |
| Thyroid stimulating hormone                   | 0.075      |
| Amylase                                       | 0.074      |
| Brain-derived neurotrophic factor             | 0.070      |
| Heart rate variability reactivity             | 0.066      |
| Evening cortisol                              | 0.053      |
| Creatinine                                    | 0.053      |
| AUCg                                          | 0.046      |

ASAT, aspartate aminotransferase; ALAT, alanine aminotransferase; Hb, hemoglobin; Ht, hematocrit; AUCl, area under the curve with respect to increase; AUCg, area under the curve with respect to the ground.
### Table 4. Distribution of characteristics across identified classes in the sample of subjects with current psychopathology

| Characteristics                                      | Lean (N = 311) | Average (N = 910) | Overweight (N = 239) | p*   |
|-------------------------------------------------------|----------------|-------------------|----------------------|------|
| **Demographics and covariates**                       |                |                   |                      |      |
| Age, mean (s.d.)                                      | 40.5 (12.23)   | 42.1 (12.59)      | 43.2 (11.49)         | 0.033|
| Sex, % female (N)                                     | 66.9 (208)     | 66.2 (602)        | 66.1 (158)           | 0.971|
| Metabolic syndrome, % (n) (medication adjusted)       | 2.7 (8)        | 18.8 (167)        | 65.3 (154)           | <0.001<sup>a,b,c</sup>|
| Number of chronic diseases                            |                |                   |                      | <0.001<sup>b</sup>|
| 0, N (%)                                              | 135 (43.4)     | 381 (41.9)        | 69 (28.9)            |      |
| 1, N (%)                                              | 102 (32.8)     | 301 (33.1)        | 74 (31.0)            |      |
| 2, N (%)                                              | 47 (15.1)      | 143 (15.7)        | 55 (23.0)            |      |
| 3+, N (%)                                             | 27 (8.7)       | 85 (9.3)          | 41 (17.1)            |      |
| **Lifestyle factors**                                 |                |                   |                      |      |
| Smokers, N (%)                                        | 48.2 (150)     | 39.9 (363)        | 43.1 (103)           | 0.035|
| Alcohol abuse (audit), mean (s.d.)                    | 5.8 (6.34)     | 4.7 (4.97)        | 3.7 (5.11)           | <0.001<sup>a,b,c</sup>|
| **Medication use**                                    |                |                   |                      |      |
| Psychotropics, % (N)                                  | 67.2 (209)     | 71.5 (651)        | 77.4 (182)           | 0.018<sup>b,c</sup>|
| SSRI, % (N)                                           | 22.5 (70)      | 26.3 (241)        | 28.4 (68)            | 0.457|
| TCA, % (N)                                            | 0.6 (2)        | 4.1 (37)          | 8.4 (20)             | <0.001<sup>b</sup>|
| Benzodiazepine, % (N)                                 | 22.2 (69)      | 24.0 (218)        | 28.0 (66)            | 0.410|
| **Current diagnosis (last month)**                    |                |                   |                      |      |
| Depression only, % (N)                                | 24.8 (77)      | 24.1 (219)        | 26.4 (63)            | 0.300|
| Anxiety only, % (N)                                   | 37.0 (115)     | 37.1 (338)        | 29.7 (71)            |      |
| Comorbidity, % (N)                                    | 38.3 (119)     | 38.5 (353)        | 43.9 (105)           |      |
| Age of onset, mean (s.d.)                             | 18.1 (11.15)   | 21.6 (12.77)      | 22.64 (12.87)        | 0.000<sup>a,b</sup>|
| **Number of depression diagnoses**                    |                |                   |                      | 0.192|
| 1, % (N)                                              | 46.6 (145)     | 48.6 (442)        | 50.2 (120)           |      |
| 2, % (N)                                              | 16.4 (51)      | 14.3 (130)        | 20.1 (48)            |      |
| **Number of anxiety diagnoses**                       |                |                   |                      | 0.425|
| 1, % (N)                                              | 47.3 (147)     | 48.9 (445)        | 42.3 (101)           |      |
| 2, % (N)                                              | 19.0 (59)      | 20.4 (186)        | 24.3 (58)            |      |
| 3, % (N)                                              | 9.0 (28)       | 6.6 (60)          | 7.2 (17)             |      |
| Months with depression symptoms, mean (s.d.)          | 21.4 (16.33)   | 20.3 (14.19)      | 21.7 (17.10)         | 0.206|
| Months with anxiety symptoms, mean (s.d.)             | 26.8 (19.46)   | 26.7 (19.57)      | 24.5 (18.29)         | 0.544|
| Months with avoidance symptoms, mean (s.d.)           | 30.3 (21.01)   | 30.6 (22.55)      | 26.6 (22.12)         | 0.192|
| **Internalizing diagnoses**                           |                |                   |                      |      |
| MDD, % (N)                                            | 53.7 (166)     | 53.3 (485)        | 63.2 (151)           | 0.020<sup>b,c</sup>|
| Minor Depression, % (N)                               | 6.4 (20)       | 5.9 (54)          | 4.2 (10)             | 0.496|
| Dysthymia, % (N)                                      | 19.6 (61)      | 17.9 (163)        | 23.0 (55)            | 0.197|
| Social phobia, % (N)                                  | 42.8 (133)     | 36.8 (335)        | 35.6 (85)            | 0.126|
| Panic W. Agoraphobia, % (N)                           | 21.9 (78)      | 25.3 (230)        | 23.8 (57)            | 0.473|
| Panic W.O. Agoraphobia, % (N)                         | 10.6 (33)      | 10.4 (35)         | 11.7 (28)            | 0.850|
| Agoraphobia, % (N)                                    | 9.6 (30)       | 10.1 (92)         | 13.0 (31)            | 0.378|
| GAD, % (N)                                            | 27.3 (85)      | 26.9 (245)        | 28.0 (67)            | 0.941|
| Depression severity (IDS), mean (s.d.)                | 29.70 (11.64)  | 30.01 (12.11)     | 34.39 (12.95)        | <0.001<sup>b</sup>|
| Anxiety Severity (BAI), Mean (s.d.)                   | 16.64 (9.98)   | 18.02 (10.48)     | 20.99 (12.57)        | <0.001<sup>b</sup>|

(Continued)
influence of underweight could not be evaluated because people with a BMI < 18.5 were rare compared with overweight persons. Fourth, to facilitate the analyses, continuous biomarker measurements were coded to a discrete scale, possibly leading to a loss of information. Latent Profile Analysis (using continuous variables) usually provides a more nuanced representation of the data. Unfortunately, this technique could not be applied to our dataset because it is very sensitive to non-normal distributions (Morgan et al., 2016). Fifth, coding was stratified for sex and age groups, but other unknown/unmeasured factors were not considered. Finally, the biological data needed to estimate the subtypes was not available at follow-up, making it impossible to investigate subtype stability over time and the effects of subtype changes over time.

In conclusion, three biological subgroups were identified with LCA among depressive and/or anxiety patients. These subgroups showed classes that (1) were strongly tied to general (metabolic) health, (2) did not reflect any natural cutoffs along the lines of the traditional diagnostic classifications, and (3) showed that especially poor metabolic health had a strong relationship with depression and anxiety and could, therefore, be seen as a distal marker for these types of psychopathology.

**Supplementary Material.** The supplementary material for this article can be found at https://doi.org/10.1017/S0033291718001307

**Acknowledgements.** The infrastructure for the NESDA study (www.nesda.nl) is funded through the Geestkracht program of the Netherlands Organisation for Health Research and Development (ZonMw, grant number 10-000-1002) and financial contributions by participating universities and mental health care organizations (VU University Medical Center, GGZ inGest, Leiden University Medical Center, Leiden University, GGZ Rivierduinen, University Medical Center Groningen, University of Groningen, Lentis, GGZ Friesland, GGZ Drenthe, Rob Giel Onderzoekscentrum). We would like to thank the Center for Information Technology of the University of Groningen for their support and for providing access to the Peregrine high performance computing cluster.

**Financial support.** Dr. Lamers has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement n° PCIG12-GA-2012-334065.

**Conflict of interest.** All authors declare that they have no conflicts of interest.

**Table 4. (Continued.)**

|                           | Lean (N = 311) | Average (N = 910) | Overweight (N = 239) | p*  |
|---------------------------|---------------|-------------------|---------------------|-----|
| Number of MDD episodes, mean (s.d.) | 4.9 (8.31) | 5.4 (11.84) | 4.7 (8.46) | 0.333 |
| IDS subscale              |               |                   |                     |     |
| Atypical, % (N)           | 15.0 (45)     | 19.6 (175)        | 28.4 (66)           | <0.001b |
| Melancholic, % (N)        | 14.3 (43)     | 10.5 (94)         | 16.0 (37)           | 0.035 |
| Bai subscale, mean (s.d.) |               |                   |                     |     |
| Somatic                   | 9.5 (6.73)    | 10.6 (7.03)       | 13.0 (8.26)         | <0.001b,c |
| Subjective                | 7.1 (4.37)    | 7.4 (4.46)        | 8.0 (5.39)          | 0.395 |

AUDIT, alcohol use disorder identification test; BAI, Beck Anxiety Inventory; BMI, body mass index; CIDIC, Composite Interview Diagnostic Instrument; GAD, generalized anxiety disorder; IDS, Inventory of Depressive Symptomatology; MDD, major depression, NA, not applicable; SSRI, selective serotonin reuptake inhibitors; TCA, tricyclic antidepressants.

*Based on ANOVA for continuous variables (post-hoc = Tukey), Kruskal-Wallis tests for non-normally distributed variables (post-hoc = Dunn test) and chi-square test for categorical variables.

Significant differences by class (at α < 0.05 corrected using the False Discovery Rate controlling method).

b ’lean’ v. ‘average’ class.

c ’lean’ v. ‘overweight’ class.

d ‘average’ v. ‘overweight’ class.

**References**

Abosi O, Lopes S, Schmitz S and Fiedorowicz JG (2018) Cardiometabolic effects of psychotropic medications. Hormone Molecular Biology and Clinical Investigation [Epub ahead of print].

Bartova L, Berger A and Pezawas L (2010) Is there a personalized medicine for mood disorders? European Archives of Psychiatry and Clinical Neuroscience 260, 121–126.

Baumeister H and Parker G (2012) Meta-review of depressive subtyping models. Journal of Affective Disorders 139, 126–140.

Beck AT, Epstein N, Brown G and Steer RA (1988) An inventory for measuring clinical anxiety: psychometric properties. Journal of Consulting and Clinical Psychology 56, 893.

Benjamin Y and Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society 57, 289–300.

Blaine B (2008) Does depression cause obesity? Journal of Health Psychology 13, 1190–1197.

Bornstein SR, Schuppens A, Wong ML and Licinio J (2006) Approaching the shared biology of obesity and depression: the stress axis as the locus of gene-environment interactions. Molecular Psychiatry 11, 902–909.

Carroll BJ (1982) Use of the dexamethasone suppression test in depression. Journal of Clinical Psychiatry 43, 44–50.

Chaves PHM, Xue QL, Guralnik JM, Ferrucci L, Volpato S and Fried LP (2004) What constitutes normal hemoglobin concentration in community-dwelling disabled older women? Journal of the American Geriatrics Society 52, 1811–1816.

Cizza G, Ronaville DS, Kleitz H, Eskandari F, Mistry S, Torvik S, Sonbolian N, Reynolds JC, Blackman MR, Gold PW, Martinez PE and P.O.W.E.R. (Prenomenopausal Women, Alendronate, Depression) Study Group O (2012) Clinical subtypes of depression are associated with specific metabolic parameters and circadian endocrine profiles in women: the power study. PloS ONE 7, e28912.

Cooney G (2013) Exercise for depression. Journal of Evidence-Based Medicine 6, 307–308.

Cramer H (1946) The two-dimensional case. In Mathematical Methods of Statistics. Princeton: Princeton University Press, p. 282.

Cuijpers P, van Straten A, Bohlmeyer E, Hollon SD and Andersson G (2010) The effects of psychotherapy for adult depression are overestimated: a meta-analysis of study quality and effect size. Psychological Medicine 40, 211–223.

Cuijpers P, Berking M, Andersson G, Quigley L, Kleiboer A and Dobson KS (2013) A meta-analysis of cognitive-behavioural therapy for adult depression, alone and in comparison with other treatments. Canadian Journal of Psychiatry 58, 376–385.
Cuijpers P, Ebert DD, Acarturk C, Andersson G and Cristea IA (2016) Personalized psychotherapy for adult depression: a meta-analytic review. *Behavior Therapy* 47, 966–980.

de Vos S, Wardenaar KJ, Bos EH, Wit EC and de Jonge P (2015) Decomposing the heterogeneity of depression at the person-, symptom-, and time-level: latent variable models versus multimode principal component analysis. *BMC Medical Research Methodology* 15, 88.

de Wit LM, van Straten A, Lamers F, Cuijpers P and Penninx BWJH (2015) Depressive and anxiety disorders: associated with losing or gaining weight over 2 years. *Psychiatry Research* 227, 230–237.

e Silva JAC (2013) Personalized medicine in psychiatry: new technologies and approaches. *Metabolism* 62, S40–S44.

Ghanei Gheshlagh R, Parizad N, Sayehmiri K, Zamanian-Azodi M and Rashidy-pour A (2015) Is there a relationship between metabolic syndrome and depression? A systematic review and meta-analysis. *Koomesh* 16, 488–494.

Gibson-Smith D, Bot M, Milaneschi Y, Twisk JW, Visser M, Brouwer IA and Penninx BWJH (2016) Major depressive disorder, antidepressant use, and subsequent 2-year weight change patterns in the Netherlands study of depression and anxiety. *Journal of Clinical Psychiatry* 77, e144–e151.

Giltay EJ, Enter D, Zitman FG, Penninx BWJH, van Pelt J, Spinohoven P and Roelofs K (2012) Salivary testosterone: associations with depression, anxiety disorders, and antidepressant use in a large cohort study. *Journal of Psychosomatic Research* 72, 205–213.

Goldberg D (2011) The heterogeneity of ‘major depression’. *World Psychiatry* 10, 226–228.

Hasler G (2010) Pathophysiology of depression: do we have any solid evidence of interest to clinicians? *World Psychiatry* 9, 155–161.

Hasler G, Drevets WC, Manji HK and Charney DS (2004) Discovering endophenotypes for major depression. *Neuropsychopharmacology* 29, 1765–1781.

Hastie T, Tibshirani R and Friedman J (2011) *The Elements of Statistical Learning: Data Mining, Inference, and Prediction*, 2nd Edn. New York: Springer Series in Statistics, pp. 501–520.

Hettema JM (2008) The nosologic relationship between generalized anxiety disorder and major depression. *Depression and Anxiety* 25, 300–316.

Hilles SA, Révész D, Lamers F, Giltay E and Penninx BWJH (2016) Bidirectional prospective associations of metabolic syndrome components with depression, anxiety, and antidepressant use. *Depression and Anxiety* 33, 754–764.

Insel T, Cuthbert B, Garvey M, Heinssen R, Pine D, Quinn K, Sanislow C and Wang P (2010) Research Domain Criteria (RDoC): toward a new classification framework for research on mental disorders. *American Journal of Psychiatry* 167, 748–751.

Kapur S, Phillips G and Insel TR (2012) Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it? *Molecular Psychiatry* 17, 1174–1179.

Kendell R and Jablensky A (2003) Distinguishing between the validity and utility of psychiatric diagnoses. *American Journal of Psychiatry* 160, 4–12.

Kendler KS (2014) The structure of psychiatric science. *American Journal of Psychiatry* 171, 931–938.

Kessler RC (2012) The costs of depression. *Psychiatric Clinics of North America* 35, 1–14.

Korte SM, Prins J, Krajc AM, Hendriksen H, Oosting RS, Westphal KG, Korte-Bouws GAH and Olivier B (2015) The many different faces of major depression: it is time for personalized medicine. *Elsevier European Journal of Pharmacology* 753, 88–104.

Lamers F, Vogelzangs N, Merikangas K, De Jonge P, Beekman A and Penninx B (2013) Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression. *Molecular Psychiatry* 18, 692–699.

Leucht AF, Cook IA, Hamilton SP, Narr KL, Toga A, Hunter AM, Faull K, Whitelegge J, Andrews AM, Loo J, Way B, Nelson SF, Horvath S and Lebowitz BD (2015) Biomarkers to predict antidepressant response. *Current Psychiatry Reports* 17, 533–562.

Licht CMM, de Geus EJC, Zitman FG, Hoogendijk WJG, van Dyck R and Penninx BWJH (2008) Association between major depressive disorder and heart rate variability in the Netherlands Study of Depression and Anxiety (NEDAS). *Archives of General Psychiatry* 65, 1358–1367.

Lojko D, Buzuk G, Owecki M, Ruchala M and Rybakowski JK (2015) Atypical features in depression: association with obesity and bipolar disorder. *Journal of Affective Disorders* 185, 76–80.

Lubke GH and Muthén B (2005) Investigating population heterogeneity with factor mixture models. *Psychological Methods* 10, 21–39.

Luppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BWJH and Zitman FG (2010) Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. *Archives of General Psychiatry* 67, 220–229.

Luppino FS, Bouvy PF, Giltay EJ, Penninx BWJH and Zitman FG (2014) The metabolic syndrome and related characteristics in major depression: inpatients and outpatients compared metabolic differences across treatment settings. *General Hospital Psychiatry* 36, 509–515.

Mannan M, Mamun A, Dö S and Clavarino A (2016) Is there a bi-directional relationship between depression and obesity among adult men and women? Systematic review and bias-adjusted meta analysis. *Asian Journal of Psychiatry* 21, 51–66.

Marazziti D, Rutigliano G, Baroni S, Landi P and Dell’Osso L (2014) Metabolic syndrome and major depression. *CNS Spectrums* 19, 293–304.

Marquand AF, Wollers T, Mennes M, Buitelaar J and Beckmann CF (2016) Beyond lumping and splitting: a review of computational approaches for stratifying psychiatric disorders. *Cognitive Neuroscience and Neuroimaging* 1, 433–447.

Meyer JM and Ginsburg GS (2002) The path to personalized medicine. *Current Opinion in Chemical Biology* 6, 434–438.

Milaneschi Y, Hoogendijk W, Lips P, Heijboer AC, Schoevers R, van Hemert AM, Beekman ATF, Smit JH and Penninx B (2014) The association between low vitamin D and depressive disorders. *Molecular Psychiatry* 19, 444–451.

Milaneschi Y, Lamers F, Bot M, Drent ML and Penninx BWJH (2017) Leptin dysregulation is specifically associated with major depression with atypical features: evidence for a mechanism connecting obesity and depression. *Biological Psychiatry* 81, 807–814.

Miller DB and O’Callaghan JP (2013) Personalized medicine in major depressive disorder—opportunities and pitfalls. *Metabolism* 62, 534–539.

Monroe SM and Anderson SF (2015) Depression: the shroud of heterogeneity. *Current Directions in Psychological Science* 24, 227–231.

Morgan GB, Hodge KJ and Baggett AR (2016) Latent profile analysis with nonnormal mixtures: a Monte Carlo examination of model selection using fit indices. *Computational Statistics and Data Analysis* 93, 146–161.

Morita T, Sznazi K, Ishihara R, Umeda K, Naga T, Hida H, Nabeshima T, Yukawa K, Ozaki N and Noda Y (2014) Plasma dehydroepiandrosterone sulfate levels in patients with major depressive disorder correlate with remission during treatment with antidepressants. *Human Psychopharmacology* 29, 280–286.

Muthen LK and Muthen BO (2007) *Mplus User’s Guide*. 5th Edn. Los Angeles, CA: Muthén & Muthén, pp. 197–200.

Nutt DJ, Ballenger JC, Sheehan D and Wittchen HU (2002) Generalized anxiety disorder: comorbidity, comparative biology and treatment. *International Journal of Neuropsychopharmacology* 5, 315–325.

Nyland KL, Asparouhov T and Muthén BO (2007) Deciding on the number of classes in latent class analysis and growth mixture modeling: a Monte Carlo simulation study. *Structural Equation Modeling* 14, 535–569.

Ozomaro U, Wahlestedt C and Nemeroff CB (2013) Personalized medicine in psychiatry: problems and promises. *BMC Medicine* 11, 132.

Patas K, Penninx BWJH, Bus BAA, Vogelzangs N, Molenjidd MI, Elzinga BM, Bosker JF and Voshaar RCO (2014) Association between serum brain-derived neurotrophic factor and plasma interleukin-6 in major depressive disorder with melancholic features. *Brain, Behavior, and Immunity* 36, 71–79.

Penninx BWJH, Beekman ATF, Smit JH, Zitman FG, Nolen WA, Spinohoven P, Cuijpers P, De Jong PJ, Van Marwijk HWJ and Assendelft WJJ (2008) The Netherlands Study of Depression and Anxiety (NEDAS): rationale, objectives and methods. *International Journal of Methods in Psychiatric Research* 17, 121–140.
Quak J, Doornbos B, Roest AM, Duivis HE, Vogelzangs N, Nolen WA, Penninx BWJH, Kema IP and de Jonge P (2014) Does tryptophan degradation along the kynurenine pathway mediate the association between pro-inflammatory immune activity and depressive symptoms? Elsevier Psychoneuroendocrinology 45, 202–210.

Rhebergen D, van der Steenstraten IM, Sunderland M, de Graaf R, Ten Have M, Lamers F, Penninx BWJH and Andrews G (2013) An examination of generalized anxiety disorder and dysthymic disorder by latent class analysis. Psychological Medicine 44, 1701–1712.

Roest AM, de Jonge P, Williams CD, de Vries YA, Schoevers RA and Turner EH (2015) Reporting bias in clinical trials investigating the efficacy of second-generation antidepressants in the treatment of anxiety disorders: a report of 2 meta-analyses. JAMA Psychiatry 72, 500–510.

Rush AJ, Gullion CM, Basco MR, Jarrett RB and Trivedi MH (1996) The inventory of depressive symptomatology (IDS): psychometric properties. Psychological Medicine 26, 477–486.

Sardinia A and Nardi AE (2014) The role of anxiety in metabolic syndrome. Expert Review of Endocrinology & Metabolism 7, 63–71.

Simon GE (2011) What little we know about tailoring depression treatment for individual patients. Depression and Anxiety 28, 435–438.

Simon GE and Perlis RH (2010) Personalized medicine for depression: can we match patients with treatments? American Journal of Psychiatry 167, 1445–1455.

Tang SW, Helmeste DM and Leonard BE (2010) Antidepressant compounds: a critical review. Depression: From Psychopathology to Pharmacotherapy 27, 1–19.

Turner EH and Rosenthal R (2008) Efficacy of antidepressants. Biomedical Journal 336, 516–517.

Van Loo HM, De Jonge P, Romeijn J-W, Kessler RC and Schoevers RA (2012) Data-driven subtypes of major depressive disorder: a systematic review. BMC Medicine 10, 156.

van Reedt Dortland AKB, Giltay EJ, van Veen T, van Pelt J, Zitman FG and Penninx BWJH (2009) Associations between serum lipids and major depressive disorder: results from the Netherlands Study of Depression and Anxiety (NESDA). Physicians Postgraduate Press, Inc. The Journal of Clinical Psychiatry 71, 1478–736.

Van Reedt Dortland AKB, Giltay EJ, Van Veen T, Zitman FG and Penninx BWJH (2010) Metabolic syndrome abnormalities are associated with severity of anxiety and depression and with tricyclic antidepressant use. Acta Psychiatrica Scandinavica 122, 30–39.

Vancampfort D, Correll CU, Wampers M, Sienaert P, Mitchell AJ, De Herdt A, Probst M, Scheewe TW and De Hert M (2014) Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables. Psychological Medicine 44, 2017–2028.

van Santen A, Vreeburg SA, Van der Does AJW, Spinhoven P, Zitman FG and Penninx BWJH (2011) Psychological traits and the cortisol awakening response: results from the Netherlands Study of Depression and Anxiety. Elsevier Psychoneuroendocrinology 36, 240–248.

Veen G, Giltay EJ, Licht CMM, Vreeburg SA, Cobbaert CM, Penninx BWJH and Zitman FG (2013) evening salivary alpha-amylase, major depressive disorder, and antidepressant use in the Netherlands Study of Depression and Anxiety (NESDA). Elsevier Psychiatry Research 208, 41–46.

Vogelzangs N, Beekman AT, van Reedt Dortland AK, Schoevers RA, Giltay EJ, de Jonge P and Penninx BW (2014) inflammatory and metabolic dysregulation and the 2-year course of depressive disorders in antidepressant users. Neuropsychopharmacology 39, 1624–1634.

Wardenaar KJ, Wanders RBK, ten Have M, de Graaf R and de Jonge P (2017) Using a hybrid subtyping model to capture patterns and dimensionality of depressive and anxiety symptomatology in the general population. Journal of Affective Disorders 215, 125–134.

Whiteford H, Ferrari A and Degenhardt L (2016) Global burden of disease studies: Implications for mental and substance use disorders. Health Affairs (Project Hope) 35, 1114–1120.

World Health Organization (WHO) (2016) Investing in treatment for depression and anxiety leads to fourfold return. (http://www.who.int/mediacentre/news/releases/2016/depression-anxiety-treatment/en/).